Understand: Niranib-100mg-Niraparib-Zejula

Niranib-100mg-Niraparib-Zejula is a medicine that helps maintain the response of specific types of the ovarian, fallopian tube, and peritoneal cancer in patients who have already responded or partially responded to other chemotherapy medications. It belongs to the PARP inhibitor class and functions by eliminating cancer cells.

Indication for Using Niranib

For Recurrent Ovarian Cancer: Niraparib 100mg maintains treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in complete or partial response to platinum-based chemotherapy. patients have to start treatment with Niraparib 8 weeks after the platinum-containing regimen. Niraparib should be continued until the disease progresses or has unacceptable toxicity.
For advanced ovarian cancer: Niraparib 100mg is the first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. In case of advanced ovarian cancer, Niraparib should be used no later than 12 weeks after the platinum-containing regimen.

Dosage and modification of Niranib-100mg-Niraparib-Zejula:

Dose reduction:

300mg starting dose:
First dose reduction: 200 mg/day
Second dose reduction: 100 mg/day
Discontinue if further dose reduction <100 mg/day required
200 mg starting dose
- First dose reduction: 100 mg/day
- Discontinue if further dose reduction <100 mg/day is required

Possible Side effect of Using Niraparib:

Administration and storage of Niranib-100mg-Niraparib-Zejula:

Niranib-100mg-Niraparib-Zejula is an orally administrated medication that comes as a capsule. patients may take it with or without food. Take the medication at the same time each day and Swallow the whole capsule. Bedtime administration may be a potential method for managing nausea. However, if you miss or vomit a dose take the next dose at its regular scheduled time. Do not take an additional dose.

Storage: Store at 20-25°C (68-77°F); excursions are permitted between 15-30°C (59-86°F). [5]

Niraparib in Prostate Cancer Treatment:

FDA has not approved this drug yet. Doctors are doing clinical trials for treating prostate cancer that has progressed after hormone therapy, with a median progression-free survival of 13.6 months. It also has potential treatment capability for resistant prostate cancer.

Niraparib and Abireterone Acetate/ Niraparib Akeega:

Prostate cancer can be treated with two drugs: niraparib and abiraterone acetate (AAP). Niraparib is a PARP inhibitor that blocks the activity of PARP. It is a protein that helps cells repair damaged DNA. Cancer cells rely on PARP to repair their DNA, so blocking it can lead to cancer cell to the death. AAP, on the other hand, is an androgen receptor (AR) inhibitor that blocks the production of testosterone, a hormone essential for prostate cancer growth.

Niraparib FDA Approval:

It has been approved by the US Food and Drug Administration (FDA) for the following indications:

Maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy This approval was granted on April 29, 2020.
Treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer that has progressed after three or more prior chemotherapy treatments in patients with a BRCA mutation (a mutation in the BRCA1 or BRCA2 gene) This approval was granted on March 27, 2017.
Treatment of adult patients with advanced high-grade serous epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer in patients with homologous recombination deficiency (HRD), regardless of BRCA mutation status This approval was granted on November 29, 2022.

Niraparib Success Rate:

Clinical trials are being conducted to study the combination of Niraparib and AAP as a treatment for prostate cancer. In a phase 3 clinical trial, the combination of these drugs was found to be effective in improving progression-free survival (PFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) with or without alterations in homologous recombination repair (HRR) genes. The results showed that patients who received the combination had a median PFS of 24.8 months, while those who received AAP alone had a median PFS of 14.8 months.

How to order Niranib-100mg-Niraparib-Zejula ?

Ordering any medicine from our website is very easy. We attach our contact info with the product image, anyone can reach us by that contact info. Or you may go to our contact us page and then send us a text referring to your query like which medicine you want to purchase, how many quantities of the product you want, which shipping method you would prefer, etc. Simply tell us the medicine name, medicine quantity, where to send I mean the country name, your mailing address. For any kind of query, you may mail us, or send a text message through WhatsApp, or WeChat at +8801304498958.